[go: up one dir, main page]

AU2001249928A1 - Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv - Google Patents

Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv

Info

Publication number
AU2001249928A1
AU2001249928A1 AU2001249928A AU4992801A AU2001249928A1 AU 2001249928 A1 AU2001249928 A1 AU 2001249928A1 AU 2001249928 A AU2001249928 A AU 2001249928A AU 4992801 A AU4992801 A AU 4992801A AU 2001249928 A1 AU2001249928 A1 AU 2001249928A1
Authority
AU
Australia
Prior art keywords
virus
hepatitis
infectious
cells
primary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249928A
Inventor
Warren Schmidt
Jack T Stapleton
Sabina Wunschmann
Jinhua Xiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
Original Assignee
University of Iowa Research Foundation UIRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation UIRF filed Critical University of Iowa Research Foundation UIRF
Publication of AU2001249928A1 publication Critical patent/AU2001249928A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001249928A 2000-04-06 2001-04-05 Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv Abandoned AU2001249928A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19559700P 2000-04-06 2000-04-06
US60/195,597 2000-04-06
US25339000P 2000-11-27 2000-11-27
US60/253,390 2000-11-27
PCT/US2001/011389 WO2001077157A2 (en) 2000-04-06 2001-04-05 FULL-LENGTH gb virus c (HEPATITIS G VIRUS) RNA TRANSCRIPTS ARE INFECTIOUS IN PRIMARY CD4 POSITIVE T CELLS AND METHODS OF TREATING HIV

Publications (1)

Publication Number Publication Date
AU2001249928A1 true AU2001249928A1 (en) 2001-10-23

Family

ID=26891123

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249928A Abandoned AU2001249928A1 (en) 2000-04-06 2001-04-05 Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv

Country Status (3)

Country Link
US (1) US6870043B2 (en)
AU (1) AU2001249928A1 (en)
WO (1) WO2001077157A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037202A2 (en) * 2002-10-24 2004-05-06 University Of Iowa Research Foundation Gb virus c and methods of treating viral infections
US20050118181A1 (en) 2003-06-05 2005-06-02 Stapleton Jack T. GB virus C (hepatitis G virus) for the treatment of HIV
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
US9611301B2 (en) * 2012-03-20 2017-04-04 The University Of Iowa Research Foundation GB virus C (hepatitis G virus) E2 glycoprotein as an immunomodulatory agent
US20160067331A1 (en) * 2013-03-15 2016-03-10 The University Of Iowa Reseach Foundation Viral proteins as immunomodulatory agents and vaccine components
KR20170066433A (en) 2014-09-17 2017-06-14 더 유니버시티 오브 아이오와 리서치 파운데이션 Viral rna segments as immunomodulatory agents and vaccine components

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620896A (en) 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5859230A (en) 1992-07-30 1999-01-12 Genelabs Technologies, Inc. Non-A/non-B/non-C/non-D/non-E hepatitis agents and molecular cloning thereof
US6156495A (en) * 1994-02-14 2000-12-05 Abbott Laboratories Hepatitis GB virus recombinant proteins and uses thereof
US5824507A (en) 1994-05-20 1998-10-20 Genelabs Technologies, Inc. Hepatitis G virus and molecular cloning thereof
US5874563A (en) 1994-05-20 1999-02-23 Genelabs Technologies, Inc. Hepatitis G virus and molecular cloning thereof
AU723313B2 (en) 1996-03-05 2000-08-24 Regents Of The University Of California, The Recombinant live feline immunodeficiency virus and proviral DNA vaccines
US5766916A (en) 1996-04-24 1998-06-16 Genelabs Technologies, Inc. Hepatitis G virus protease
US5958895A (en) 1996-10-23 1999-09-28 American Home Products Corporation DNA vaccines for herpes simplex virus
CN1058751C (en) * 1998-06-15 2000-11-22 中国人民解放军第二军医大学 Full length CDNA clone of hepatitis virus G genome and its construction method
AU5460900A (en) * 1999-06-04 2000-12-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious cdna clone of gb virus b and uses thereof

Also Published As

Publication number Publication date
US6870043B2 (en) 2005-03-22
WO2001077157A2 (en) 2001-10-18
WO2001077157A3 (en) 2002-08-01
US20030170870A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
EP1292603B8 (en) Methods and compositions for treating hepatitis c virus
WO2000053729A3 (en) Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
IL137510A0 (en) Compositions comprising viruses and methods for concentrating virus preparations
AU2002338666A1 (en) Multiplication of viruses in a cell culture
AU2003284689A1 (en) NUCLEIC ACID CONSTRUCT CONTAINING HEPATITIS C VIRUS (HCV) OF GENOCYPE 2a GENOME-ORIGIN NUCLEIC ACID AND CELL HAVING THE NUCLEIC ACID CONSTRUCT TRANSFERRED THEREINTO
AU2002221033A1 (en) Cells to be used in producing virus vector, process for producing the same and process for producing virus vector with the use of the cells
EP1322325A4 (en) Inhibiting hepatitis c virus processing and replication
WO2003015708A3 (en) Composition and method for treating hiv infection
IL153388A0 (en) Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof
EP1592445A4 (en) Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
AU2001249928A1 (en) Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
WO2002038792A3 (en) Novel method for analysing phenotypic characteristics of human immunodeficiency virus (hiv)
WO2003053332A3 (en) Composition and method for treating viral infection
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
WO2003013425A3 (en) In vitro assays for inhibitors of hiv capsid conformational changes and for hiv capsid formation
AU2001263096A1 (en) Compositions and methods for production of rna viruses and rna virus-based vector particles
AU2003287216A1 (en) Gb virus c and methods of treating viral infections
AU2001277067A1 (en) Papillomavirus infected epithelial cells and methods of producing infectious papillomavirus in epithelial cells and uses thereof
AU4451601A (en) Genetically engineered clone of hepatitis e virus (hev) genome which is infectious, its production and uses
WO2002004595A3 (en) Production of chimeric human papillomavirus
WO2002061048A3 (en) In vitro system for replication of rna-dependent rna polymerase (rdrp) viruses
ZA200402353B (en) Methods of treating liver fibrosis and hepatitis C virus infection
AU2001282560A1 (en) Methods of infection with hepatitis c virus